Leukemia

Investigational Compound Offers Promise for AML Patients

Published in Cancer Weekly, June 2nd, 1997

Preliminary results presented at the annual meeting of the American Society of Clinical Oncology, held in Denver, Colorado, indicate a potential advance in the treatment of acute myelogenous leukemia (AML) - one of the most aggressive forms of bone marrow cancer.

Data were presented from a clinical trial of 39 patients with an investigational compound known as CMA-676. The compound is being co-developed by Celltech plc (UK) and Wyeth-Ayerst Research of Radnor, PA. The study was intended to determine the appropriate dosing for leukemia patients. During this process, the product displayed preliminary evidence of efficacy, with two patients achieving complete remission...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry